timothy sykes logo
MIRM Stock Jumps As HDV Data Fuel Bullish Targets Thumbnail
G Google News

MIRM Stock Jumps As HDV Data Fuel Bullish Targets

ELLIS HOBBS•UPDATED MAY. 4, 2026, 2:33 PM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Mirum Pharmaceuticals Inc. stocks have been trading up by 10.55 percent amid strong sentiment on positive clinical and regulatory developments.

Candlestick Chart

Live Update At 14:33:00 EDT: On Monday, May 04, 2026 Mirum Pharmaceuticals Inc. stock [NASDAQ: MIRM] is trending up by 10.55%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Mirum Pharmaceuticals (MIRM) is acting like a biotech name with real momentum behind the story. On the tape, MIRM just put in a huge range day, opening around $89.50 and ripping to an intraday high above $110 before closing near $106.72. That is a massive expansion from the prior cluster of closes in the mid‑$90s, and it tells traders that fresh money is piling in on the HDV news.

Zooming out, the daily chart for MIRM shows a steady grind from the low‑$90s to mid‑$90s over recent sessions, then a clear breakout day on heavy action. Intraday 5‑minute candles show consolidation above $107 for hours, which is important: strong names typically hold most of their gains after a catalyst instead of fading back.

Fundamentally, Mirum Pharmaceuticals is still losing money, with a recent quarterly net loss of about $5.7M and negative earnings per share. But revenue is growing fast, with roughly $149M in quarterly revenue and strong gross margin above 100%, typical for rare‑disease drugs with high pricing. MIRM carries leverage, yet a current ratio of 2.7 and close to $300M in cash give it room to fund trials. For traders, this is a classic high‑growth, high‑valuation biotech: you are trading data and momentum more than current profits.

Why Traders Are Watching MIRM Right Now

MIRM is front and center on many traders’ screens because the HDV story just shifted from “interesting” to “real.” Mirum Pharmaceuticals reported that its monoclonal antibody brelovitug hit the primary endpoint in the Phase 2b AZURE‑1 trial for chronic hepatitis delta virus. That is not just a minor win. The trial showed strong antiviral activity, liver enzyme (ALT) normalization, and a favorable safety profile — all the boxes you want checked before risking capital on a Phase 3 swing.

More detail matters for traders. In AZURE‑1, brelovitug nailed the primary composite endpoint, with a striking 100% virologic response in the 300 mg weekly arm and strong responses even with 900 mg monthly dosing. Good tolerability on top of that positions brelovitug as a potential single‑agent therapy in HDV, which is a serious unmet medical need. When the science is this clean, the Street is more willing to model real future cash flows.

That is exactly what happened. H.C. Wainwright raised its MIRM price target from $130 to $150 and kept a Buy rating, explicitly pointing to the AZURE‑1 data and calling Mirum Pharmaceuticals a top pick. Baird followed, pushing its MIRM target to $112 from $95, arguing the Phase 2b data validate the Bluejay acquisition that brought this HDV asset in‑house. Stifel also bumped its target to $130 and reiterated Buy.

Stack those calls together and you have a consensus wall of bullish sell‑side support under MIRM. Add a clear catalyst path — Phase 3 AZURE‑1/4 topline data expected in H2 2026, with a potential U.S. BLA filing and launch in 2027 — and traders can actually anchor swing theses to a concrete timeline.

On top of HDV, Mirum Pharmaceuticals lined up more news flow. The company will host a 2026/05/04 call to lay out VISTAS topline results for volixibat in primary sclerosing cholangitis. That PSC asset, plus an established rare‑disease portfolio, gives MIRM multiple shots on goal. Upcoming Q1 2026 results and a corporate update call should also give traders more detail on cash runway, trial funding, and commercial traction. Even standard items — like inducement option and RSU grants to new hires — show Mirum Pharmaceuticals is still building out the team to support a broader pipeline.

More Breaking News

Conclusion

For active traders, MIRM is a live case study in how strong data, analyst upgrades, and a clear catalyst path can re‑rate a biotech stock fast. Mirum Pharmaceuticals delivered what the market wanted on AZURE‑1: clean Phase 2b brelovitug data with 100% virologic response in a key dosing arm, ALT normalization, and tolerability that supports chronic use. That gave MIRM the fuel to break out on the chart and hold higher levels through the session.

But this move is not just about one headline. With Phase 3 AZURE‑1/4 topline data due in H2 2026 and a potential BLA filing and 2027 launch on the table, traders now have a playbook for staging multi‑month swings around each data point. The raised price targets from H.C. Wainwright, Baird, and Stifel give Mirum Pharmaceuticals an added psychological tailwind — traders love seeing the Street chase a name higher.

At the same time, MIRM remains a classic high‑risk biotech. The company is not consistently profitable yet, and valuation ratios show the market is already pricing in substantial future success. That is why discipline matters. As Tim Sykes likes to say, “Cut losses quickly and don’t fall in love with any stock — there’s always another play.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. Apply that mindset to MIRM: respect the trend, know the catalysts, and keep your risk tight. This article is for educational and research purposes only and is not trading advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading MIRM

Millionaire's
POV on MIRM

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”